文献速递骨肿瘤关节外科

清创、抗生素与植入物保留(DAIR)联合方案在肿瘤型巨型假体假体周围感染中的治疗成功率与二期翻修相似

Debridement, Antibiotics, and Implant Retention (DAIR) Plus Offers Similar Periprosthetic Joint Infection Treatment Success Rates to Two-Stage Revision in Oncologic Megaprosthesis.
PubMed 文献 · J Arthroplasty · 2024-01-14

该回顾性研究分析了67例肿瘤型巨型假体植入后假体周围感染(PJI)患者,按手术策略分为DAIR组14例、DAIR联合组31例和二期翻修组21例。DAIR联合组或二期翻修组的2年无再感染生存率为60%,高于DAIR组的25%(P=0.049);DAIR联合组与二期翻修组在2年和5年无再感染、无再手术及无截肢生存率相似。作者认为DAIR联合方案不劣于二期翻修,或可用于无法耐受二期翻修手术的患者。

要点

  • DAIR组2年无再感染生存率为25%,DAIR联合组或二期翻修组为60%(P=0.049)。
  • DAIR联合组与二期翻修组在2年和5年无再感染、无再手术及无截肢生存率相似。
  • 体重指数≥30(HR=2.65)和慢性肾脏病(HR=11.53)是再感染的危险因素。

核心结论

  • DAIR与较高的治疗失败率和截肢率相关,高于DAIR联合方案或二期手术。
  • DAIR联合方案在清除PJI方面不劣于二期翻修,作者认为或可用于无法耐受二期翻修手术的患者。

研究设计与样本

  • 回顾性分析肿瘤适应症巨型假体植入后诊断为PJI的患者,采用2011年肌肉骨骼感染学会标准定义PJI。
  • 共纳入67例巨型假体PJI患者,其中DAIR组14例、DAIR联合组(DAIR联合模块组件更换并保留柄)31例、二期翻修组21例。
  • 采用Kaplan-Meier法进行生存分析,Cox比例风险模型进行危险因素分析。

主要发现

  • 2年无再感染生存率:DAIR组为25%,DAIR联合组或二期翻修组为60%(P=0.049)。
  • 5年无截肢生存率:DAIR联合组或二期翻修组为84%,DAIR组为48%(P=0.13)。
  • DAIR联合组与二期翻修组在2年和5年无再感染、无再手术及无截肢生存率相似。
  • 体重指数≥30(HR=2.65)和慢性肾脏病(HR=11.53)是再感染的危险因素。
  • DAIR联合方案或二期翻修治疗(HR=0.44)是再感染的保护因素。

临床怎么用

  • 作者认为DAIR联合方案在清除PJI方面不劣于二期翻修,或可用于无法耐受二期翻修手术的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prosthetic joint infections (PJIs) after megaprosthesis implantation are associated with high rates of treatment failure and amputation. Our study analyzed PJI treatment success rates by surgical strategy and assessed risks of reinfection and amputation. METHODS: We retrospectively analyzed the outcomes of patients diagnosed with PJI after undergoing megaprosthesis implantation for oncologic indications. The 2011 Musculoskeletal Infection Society criteria were used to define PJI. Reinfection, reoperation, and amputation for PJI recurrence were assessed. A total of 67 patients with megaprosthesis PJIs were included. There were fourteen patients who were treated with debridement, antibiotics, and implant retention (DAIR), 31 with DAIR plus (DAIR with modular component exchange and stem retention), and 21 with two-stage revisions. Kaplan-Meier estimates were used for survival analyses and Cox proportional hazards for risk factor analyses. RESULTS: The two-year reinfection-free survival was 25% for DAIR and 60% for DAIR plus or two-stage revision (P = .049). The five-year amputation-free survival was 84% for DAIR plus or two-stage revision, and 48% for DAIR (P = .13). Reinfection-free, reoperation-free, and amputation-free survival were similar between DAIR plus and two-stage revision at the 2- and 5-year marks. Body mass index ≥30 (hazard ratio [HR] = 2.65) and chronic kidney disease (HR = 11.53) were risk factors for reinfection. Treatment with DAIR plus or two-stage revision (HR = 0.44) was a protective factor against reinfection. CONCLUSIONS: A DAIR was associated with high rates of treatment failure and higher amputation rates than DAIR plus or 2-stage surgery. A DAIR plus was not inferior to 2-stage revision clearing a PJI and might be performed in patients who cannot withstand two-stage revision surgery.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Gonzalez MR, Acosta JI, Clunk MJ, et al. Debridement, Antibiotics, and Implant Retention (DAIR) Plus Offers Similar Periprosthetic Joint Infection Treatment Success Rates to Two-Stage Revision in Oncologic Megaprosthesis. J Arthroplasty. 2024. PMID: 38224789. doi:10.1016/j.arth.2024.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。